AERI - Earnings announcements

Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022   Aerie Expects to be Cash Flow Break Even During 2024 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024. "Aerie delivered a s

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details: Date:   August 4, 2022 Conference call Time:   5:00 p.m. ET Suggested Dial-in Time:   15 minutes prior to ensure time for any required software download Dial-in Registration:  

First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022. "We continue to execute well on our three strategic pillars to build out

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details:   Date:   May 5, 2022 Conference call Time:   5:00 p.m. ET Suggested Dial-in Time   15 minutes prior to ensure time for any required software download Webcast:   http:/

2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million, up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise Forecasted Net Revenues, up 16% to 25% Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022. "I am delighted to join Aerie at such an exciting time of our growth trajectory and pleased

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will be released after the market closes on Thursday, February 24, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details:   Date:   February 24, 2022 Conference call Time:   5:00 p.m. ET Suggested Dial-in Time   15 minutes prior to ensure time for any required software download Webcast:

Third Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020  Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Quarter 2020 Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half of 2022 Conference Call and Webcast Today, November 4th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a general business update. "Our third quarter 2021 results reflect nearly 46 percent growth in net revenues and 26 percent growth in bottle volumes for our U.S. glaucoma franchise compared to the third

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company's website at http://investors.aeriepharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) ("AR-15512") ophthalmic solution for the treatment of patients with dry eye disease. Management will host a conference call and provide

Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Quarter of 2021 Conference Call and Webcast Today, August 4th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a general b

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company's website at http://investors.aerieph